.Attribute Medicine, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ state-of-the-art breast cancer and also energetic or stable brain metastases showed constant intracranial activity and also wide spread efficiency of T-DXd.